Comparative Pharmacology
Head-to-head clinical analysis: HOMATROPINE METHYLBROMIDE AND HYDROCODONE BITARTRATE versus SANCTURA XR.
Peer-Reviewed Evidence
Head-to-head clinical analysis: HOMATROPINE METHYLBROMIDE AND HYDROCODONE BITARTRATE versus SANCTURA XR.
HOMATROPINE METHYLBROMIDE AND HYDROCODONE BITARTRATE vs SANCTURA XR
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Hydrocodone is a mu-opioid receptor agonist; homatropine methylbromide is an anticholinergic that reduces gastrointestinal motility and secretions.
Trospium is an antimuscarinic agent that competitively inhibits acetylcholine at muscarinic receptors, reducing bladder detrusor muscle contractions.
1 tablet (containing homatropine methylbromide 5 mg and hydrocodone bitartrate 5 mg) orally every 4 to 6 hours as needed for cough. Maximum 6 tablets per 24 hours.
60 mg orally once daily, taken with a full glass of water at least 1 hour before meals. Extended-release capsule.
None Documented
None Documented
Hydrocodone: Terminal elimination half-life 3.8-6.4 hours (mean ~4.5 h) in adults; prolonged in hepatic/renal impairment (up to 12-15 h). Homatropine methylbromide: Terminal half-life ~4-6 hours via quaternary structure limiting CNS penetration.
Terminal elimination half-life is approximately 7-10 hours in patients with normal renal function; prolonged to 20-30 hours in moderate to severe renal impairment.
Hydrocodone: Renal excretion of metabolites (hydromorphone, norhydrocodone) as glucuronide conjugates (~60%) and unchanged drug (<10%). Biliary/fecal elimination accounts for ~20-30%. Homatropine methylbromide: Predominantly fecal elimination via biliary excretion as unchanged quaternary ammonium compound (~70-80%); renal excretion of unchanged drug (~10-20%).
Primarily renal excretion (70-80% as unchanged drug and active metabolite); approximately 10% fecal; 5-10% biliary.
Category D/X
Category C
Anticholinergic
Anticholinergic